1-Cinnamyl-4-(2-methoxyphenyl)piperazines: Synthesis, binding properties, and docking to dopamine (D2) and serotonin (5-HT1A) receptors

Archiv der Pharmazie

Volumn 340, Issue 9, 2007, Pages 456-465

  Penjišević, Jelena ^a   Šukalović, Vladimir ^a   Andrić, Deana ^b   Kostić Rajačić, Sladjana ^a   Šoškić, Vukić ^c   Roglić, Goran ^b  

^a Institute for Chemistry   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c PROTEOSYS AG   (Germany)

Author keywords

5 HT2A receptor; Dopamine D2 receptor; Piperazines; Serotonin 5 HT1A

Indexed keywords

1 [3 (2 CHLOROPHENYL)PROP 2 ENYL] 4 (2 METHOXYPHENYL)PIPERAZINE; 1 [3 (3 CHLOROPHENYL)PROP 2 ENYL] 4 (2 METHOXYPHENYL)PIPERAZINE; 1 [3 (4 CHLOROPHENYL)PROP 2 ENYL] 4 (2 METHOXYPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 (2 METHOXYPHENYL) 1 (3 PHENYLPROP 2 ENYL)PIPERAZINE; 4 (2 METHOXYPHENYL) 1 (3 PHENYLPROPYL)PIPERAZINE; 4 (2 METHOXYPHENYL) 1 [3 (2 METHOXYPHENYL)PROP 2 ENYL]PIPERAZINE; 4 (2 METHOXYPHENYL) 1 [3 (3 METHOXYPHENYL)PROP 2 ENYL]PIPERAZINE; 4 (2 METHOXYPHENYL) 1 [3 (3 NITROPHENYL)PROP 2 ENYL]PIPERAZINE; 4 (2 METHOXYPHENYL) 1 [3 (4 METHOXYPHENYL)PROP 2 ENYL]PIPERAZINE; 4 (2 METHOXYPHENYL) 1 [3 (4 NITROPHENYL)PROP 2 ENYL]PIPERAZINE; 4 (2 METHOXYPHENYL) 3 (2 NITROPHENYLPROP 2 ENYL)PIPERAZINE; ASPARTIC ACID; CINNAMYL 4 (2 METHOXYPHENYL)PIPERAZINE; DOPAMINE RECEPTOR; HALOPERIDOL; HISTIDINE; KETANSERIN; NEUROLEPTIC AGENT; PHENYLALANINE; PIPERAZINE DERIVATIVE; PRAZOSIN; SERINE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; THREONINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HYDROGEN BOND; PRIORITY JOURNAL;

ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING SITES; PIPERAZINES; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34748901387     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700062     Document Type: Article

References (31)

1. A. Farah, J. Clin. Psychiatry 2005, 7, 268-274.
2. M. S. Stahl, J. Clin. Psychiatry 2003, 5, 9-13.
3. L. Shi, J. A. Javitch, Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
4. V. Šoškić, J. Joksimović, Curr. Med. Chem. 1998, 5, 493-512.
5. G. Roglić, D. Andrić, S. Kostić- Rajačić, S. Dukić, V. Šoškić, Arch. Pharm. Pharm. Med. Chem. 2001, 334, 375-380.
6. V. Šukalović, M. Zlatović, D. Andrić, G. Roglić, et al., Arch. Pharm. Pharm. Med. Chem. 2004, 337, 502-512.
7. M. V. Zlatović, V. V. Šukalović, C. Schneider, G. M. Roglić, Bioorg. Med. Chem. 2006, 14, 2994-3001.
8. G. A. Pinna, G. Murineddu, M. M. Curzu, S. Villa, et al., Farmaco 2000, 55, 553-562.
9. W. Eberbach, U. Trostmann, Chem. Ber. 1981, 114, 2979-3003.
10. K. Soai, S. Yokoyama, K. Mochida, Synthesis 1987, 647-648.
11. P. Metrangolo, H. Neukirch, T. Pilati, G. Resnati, Acc. Chem. Res. 2005, 38, 386-395.
12. P. Politzer, P. Lane, M. C. Concha, Y. Ma, J. S. Murray, J. Mol. Model. 2007, 13, 305-311.
13. A. Zhang, J. L. Neumeyer, R. J. Baldessarini, Chem. Rev. 2007, 107, 274-302.
14. K. Bondensgaard, M. Ankersen, H. Thøgersen, B. S. Hansen, et al., J. Med. Chem. 2004, 47, 888-899.
15. R. B. Westkaemper, R. A. Glennon, Curr. Top. Med. Chem. 2002, 2, 575-598.
16. A. Leonardi, D. Barlocco, F. Montesano, G. Cignarella, et al., J. Med. Chem. 2004, 47, 1900-1918.
17. R. Menegatti, A. C. Cunha, V. F. Ferreira, E. F. R. Perreira, et al., Bioorg. Med. Chem. 2003, 11, 4807-4813.
18. X. Zhang, K. Hodgetts, S. Rachwal, H. Zhao, et al., J. Med. Chem. 2000, 43, 3923-3932.
19. R. A. Glennon, Drug. Dev. Res. 1992, 26, 251-124.
20. H. E. Katerinopoulos, D. I. Schuster, Drugs Future 1987, 12, 233-253.
21. R. Fausto, M. J. S. Ribeiro, J. J. Pedroso de Lima, J. Mol. Struct. 1999, 484, 181-196.
22. M. M. Teeter, M. Froimowitz, J. B. Stec, C. J. DuRand, J. Med. Chem. 1994, 37, 2874-2888.
23. R. E. Wilcox, W. H. Huang, M. Y. Brusniak, D. M. Wilcox, et al., J. Med. Chem. 2000, 43, 3005-3019.
24. K. A. Neve, M. G. Cumbay, K. R. Thompson, R. Yang, et al., Mol. Pharmacol. 2001, 60, 373-381.
25. J. A. Ballesteros, L. Shi, J. A. Javitch, Mol. Pharmacol. 2001, 60, 1-19.
26. K. Palczewski, T. Kumasaka, T. Hori, C. A. Behnke, et al., Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 5982-5987.
27. Insight II, Binding Site Analysis, Affinity, Discover, and DS Visualiser are molecular modelling software, corresponding modules and visualization software from Accelrys, Inc., San Diego, CA, USA (http://www.accelrys.com).
28. SGI Octane2 is a trademark of Silicon Graphics, Inc, CA, USA (http://www.sgi.com).
29. PovRay, Persistence of Vision Raytrace is trademark of PovRay team, (http://www.povray.org).
30. V. Šoškić, A. Maelicke, G. Petrović, B. Ristić, J. Petrović, J. Pharm. Pharmacol. 1999, 43, 27-31.
31. GraphPad Prism, GraphPad Software (http://www.graphpad.com).